The evaluation of noninferiority for renal composite outcomes between sodium –glucose cotransporter inhibitors in Japan

Cardiovascular outcome trials (CVOTs) have been performed using empagliflozin (EMPA-REG OUTCOME trial) [1,2], dapagliflozin (DECLARE-TIMI58) [3], and canagliflozin (CANVAS/CANVAS-R) [4] to demonstrate improvement in renal and cardiovascular events, yielding significant and strong evidence in meta-analyses. We also retrospectively reported the improvement of the urine albumin-to-creatinine ratio (ACR) in Japanese patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in clinical practice [5].

Source: Primary Care Diabetes - September 4, 2021 Category: Primary Care Authors: Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori Tags: Original research Source Type: research